Form 4: Immunovant CEO Sells Shares to Cover Tax Obligations After RSU Vesting
SEC Form 4 Filing
Immunovant CEO Peter Salzmann sold 8,321 shares of common stock on April 16, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- On April 16, 2025, Peter Salzmann, the CEO of Immunovant, Inc., sold 8,321 shares of Immunovant's common stock.
- The sale was executed to cover tax withholding obligations associated with the vesting of 15,240 restricted stock units (RSUs) on April 12, 2025.
- The shares were sold at a weighted average price of $14.89, with individual transactions ranging from $14.74 to $15.40 per share.
- Following the transaction, Salzmann still beneficially owns 1,178,191 shares of Immunovant common stock.
- The sale was mandated by Immunovant's policy requiring tax obligations to be funded through a 'sell to cover' transaction.
Sentiment
Score: 6
Explanation: The document describes a routine transaction (sell to cover taxes on vested RSUs). It's neutral in sentiment as it doesn't indicate any significant positive or negative developments for the company.
Industry Context
Executive stock sales are a common occurrence, particularly around vesting events. The 'sell to cover' mechanism is a standard practice to manage tax obligations, and this transaction appears to be routine.
Key Dates
| Date | Description |
|---|---|
| April 12, 2023 | Date the holder was granted 243,832 restricted stock units (RSUs). |
| April 14, 2023 | Date of Form 4 filing reporting the grant of 243,832 RSUs. |
| April 12, 2025 | Date 15,240 of the RSUs vested. |
| April 16, 2025 | Date of the stock sale transaction to cover tax obligations. |
| April 17, 2025 | Date of the Form 4 filing. |
Keywords
Immunovant, Peter Salzmann, CEO, stock sale, Form 4, RSU vesting, tax obligations, IMVT
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.